Literature DB >> 12528088

Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure.

Matej Podbregar1, Gorazd Voga.   

Abstract

BACKGROUND: In chronic heart failure (CHF) beta-blockers reduce myocardial oxygen consumption and improve myocardial efficiency by shifting myocardial substrate utilization from increased free fatty acid oxidation to increased glucose oxidation. The effect of selective and nonselective beta-blockers on total body resting energy production rate (EPR) and substrate utilization is not known.
METHODS: Twenty-six noncachectic patients with moderately severe heart failure (New York Heart Association class II or III, left ventricular ejection fraction < 0.40) were treated with carvedilol (37.5 +/- 13.5 mg/12 h) or bisoprolol (5.4 +/- 3.0 mg/d) for 6 months. Indirect calorimetry was performed before and after 6 months of treatment.
RESULTS: Resting EPR was decreased in carvedilol (5.021 +/- 0.803 to 4.552 +/- 0.615 kJ/min, P <.001) and bisoprolol group (5.230 +/- 0.828 to 4.978 +/- 0.640 kJ/min, P <.05; nonsignificant difference between groups). Lipid oxidation rate decreased in carvedilol and remained unchanged in bisoprolol group (2.4 +/- 1.4 to 1.5 +/- 0.9 mg m(2)/kg min versus 2.7 +/- 1.1 to 2.5 +/- 1.1 mg m(2)/kg min, P <.05). Glucose oxidation rate was increased only in carvedilol (2.6 +/- 1.4 to 4.4 +/- 1.6 mg m(2)/kg min, P <.05), but did not change in bisoprolol group.
CONCLUSIONS: Both selective and nonselective beta-blockers reduce total body resting EPR in noncachectic CHF patients. Carvedilol compared to bisoprolol shifts total body substrate utilization from lipid to glucose oxidation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12528088     DOI: 10.1054/jcaf.2002.130238

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  13 in total

Review 1.  Heart failure and loss of metabolic control.

Authors:  Zhao V Wang; Dan L Li; Joseph A Hill
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

2.  Beta blockers and glucose metabolism in chronic heart failure: friend or foe?

Authors:  W Doehner; S D Anker
Journal:  Clin Res Cardiol       Date:  2008-01       Impact factor: 5.460

Review 3.  Cardiac energy metabolic alterations in pressure overload-induced left and right heart failure (2013 Grover Conference Series).

Authors:  Sowndramalingam Sankaralingam; Gary D Lopaschuk
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 4.  Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting.

Authors:  Astrid Breitbart; Mannix Auger-Messier; Jeffery D Molkentin; Joerg Heineke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-03-18       Impact factor: 4.733

5.  Deranged Cardiac Metabolism and the Pathogenesis of Heart Failure.

Authors:  Gabriele Fragasso
Journal:  Card Fail Rev       Date:  2016-05

6.  Near-infrared spectroscopy during stagnant ischemia estimates central venous oxygen saturation and mixed venous oxygen saturation discrepancy in patients with severe left heart failure and additional sepsis/septic shock.

Authors:  Hugo Mozina; Matej Podbregar
Journal:  Crit Care       Date:  2010-03-23       Impact factor: 9.097

7.  Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure.

Authors:  D Kovacić; M Marinsek; L Gobec; M Lainscak; M Podbregar
Journal:  Clin Res Cardiol       Date:  2007-08-17       Impact factor: 5.460

Review 8.  Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.

Authors:  William H Frishman; Linda S Henderson; Mary Ann Lukas
Journal:  Vasc Health Risk Manag       Date:  2008

Review 9.  Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.

Authors:  Dianne M Perez
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

Review 10.  New directions in the treatment of heart failure: targeting free fatty acid oxidation.

Authors:  Gabriele Fragasso; Roberto Spoladore; Giorgio Bassanelli; Amarild Cuko; Chiara Montano; Anna Salerno; Alberto Margonato
Journal:  Curr Heart Fail Rep       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.